Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia.

IF 1.8 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Yi-Chen Wang, Hsin-Yu Ho, Lan-Pin Kuo, Shih-Yuan Fang, Meng-Hsuan Chiu, Zhi-Yan Liu, Chen-Fuh Lam, Yu-Ching Huang, Jun-Neng Roan
{"title":"Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia.","authors":"Yi-Chen Wang, Hsin-Yu Ho, Lan-Pin Kuo, Shih-Yuan Fang, Meng-Hsuan Chiu, Zhi-Yan Liu, Chen-Fuh Lam, Yu-Ching Huang, Jun-Neng Roan","doi":"10.6515/ACS.202407_40(4).20240510A","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Few evidence-based medications to improve the primary patency of arteriovenous fistulas in patients with diabetes who require hemodialysis are available. We investigated whether proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) could improve arteriovenous fistula function through pleiotropic effects in a rat model of hyperglycemia.</p><p><strong>Methods: </strong><i>Ex vivo</i> effects of PCSK9i on the aorta of Sprague-Dawley (SD) rats were investigated using an organ bath system. For in vivo experiments, an abdominal aortocaval (AC) fistula was generated in SD rats (200-250 g) after inducing hyperglycemia through streptozotocin administration (80 mg/kg, intraperitoneal). Alirocumab (50 mg/kg/week, subcutaneous) was administered on the day of fistula surgery and day 7. Echocardiography, blood flow through the aorta-limb, vasomotor reactivity, and serum biochemistry were examined on D14. Furthermore, enzyme-linked immunosorbent assay and immunoblotting were performed.</p><p><strong>Results: </strong>PCSK9i induced aorta relaxation <i>ex vivo</i> through a potassium channel-associated mechanism. PCSK9i significantly improved blood flow and preserved endothelial function without changes in cardiac function and serum lipid levels in rats with hyperglycemia. The levels of lectin-like oxidized low-density lipoprotein receptor-1, superoxide dismutase, cyclooxygenase-2, caspase-1, and interleukin-1β were significantly reduced in the treatment group. PCSK9i decreased the ratio of phosphorylated to total p38 mitogen-activated protein kinase and extracellular signal-regulated kinase in the aorta of rats with hyperglycemia.</p><p><strong>Conclusions: </strong>Short-term treatment with PCSK9i preserved endothelial function, induced vascular dilatation, and increased blood flow in the AC fistula of rats with hyperglycemia. The pleiotropic mechanisms were associated with the suppression of oxidative stress and tissue inflammation during hyperglycemia.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"40 4","pages":"421-436"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261354/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202407_40(4).20240510A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Few evidence-based medications to improve the primary patency of arteriovenous fistulas in patients with diabetes who require hemodialysis are available. We investigated whether proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) could improve arteriovenous fistula function through pleiotropic effects in a rat model of hyperglycemia.

Methods: Ex vivo effects of PCSK9i on the aorta of Sprague-Dawley (SD) rats were investigated using an organ bath system. For in vivo experiments, an abdominal aortocaval (AC) fistula was generated in SD rats (200-250 g) after inducing hyperglycemia through streptozotocin administration (80 mg/kg, intraperitoneal). Alirocumab (50 mg/kg/week, subcutaneous) was administered on the day of fistula surgery and day 7. Echocardiography, blood flow through the aorta-limb, vasomotor reactivity, and serum biochemistry were examined on D14. Furthermore, enzyme-linked immunosorbent assay and immunoblotting were performed.

Results: PCSK9i induced aorta relaxation ex vivo through a potassium channel-associated mechanism. PCSK9i significantly improved blood flow and preserved endothelial function without changes in cardiac function and serum lipid levels in rats with hyperglycemia. The levels of lectin-like oxidized low-density lipoprotein receptor-1, superoxide dismutase, cyclooxygenase-2, caspase-1, and interleukin-1β were significantly reduced in the treatment group. PCSK9i decreased the ratio of phosphorylated to total p38 mitogen-activated protein kinase and extracellular signal-regulated kinase in the aorta of rats with hyperglycemia.

Conclusions: Short-term treatment with PCSK9i preserved endothelial function, induced vascular dilatation, and increased blood flow in the AC fistula of rats with hyperglycemia. The pleiotropic mechanisms were associated with the suppression of oxidative stress and tissue inflammation during hyperglycemia.

9型蛋白转换酶抑制剂可改善高血糖大鼠动静脉瘘的血管功能
目的:目前很少有循证药物可改善需要血液透析的糖尿病患者动静脉瘘的原发性通畅性。我们研究了在高血糖大鼠模型中,蛋白转换酶亚基酶/kexin 9 型抑制剂(PCSK9i)是否能通过多效应改善动静脉瘘的功能:方法:利用器官浴系统研究了 PCSK9i 对 Sprague-Dawley (SD) 大鼠主动脉的体内外影响。在体内实验中,通过注射链脲佐菌素(80 毫克/千克,腹腔注射)诱导高血糖后,在 SD 大鼠(200-250 克)体内形成腹主动脉(AC)瘘。在瘘管手术当天和第 7 天给予阿利珠单抗(50 毫克/千克/周,皮下注射)。第14天检查超声心动图、主动脉-肢体血流量、血管运动反应性和血清生化指标。此外,还进行了酶联免疫吸附试验和免疫印迹:结果:PCSK9i通过钾通道相关机制诱导体内主动脉松弛。PCSK9i能明显改善高血糖大鼠的血流量并保护内皮功能,而不会改变心脏功能和血清脂质水平。在治疗组中,凝集素样氧化低密度脂蛋白受体-1、超氧化物歧化酶、环氧化酶-2、Caspase-1和白细胞介素-1β的水平明显降低。PCSK9i可降低高血糖大鼠主动脉中磷酸化p38丝裂原活化蛋白激酶和细胞外信号调节激酶与总p38丝裂原活化蛋白激酶的比率:结论:PCSK9i的短期治疗可保护高血糖大鼠主动脉瘘管的内皮功能、诱导血管扩张并增加血流量。这些多效应机制与抑制高血糖时的氧化应激和组织炎症有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Cardiologica Sinica
Acta Cardiologica Sinica 医学-心血管系统
CiteScore
2.90
自引率
15.80%
发文量
144
审稿时长
>12 weeks
期刊介绍: Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信